$AUTL earnings report

AUCATZYL net product revenue rose 95% year-over-year to $41.2 million; company now expects full-year 2026 AUCATZYL net product revenue at or exceeding the upper end of $150 million. AlphAI read Autolus Therapeutics's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readAUTL · Q3 2026 · ended 2026-09-30

AUCATZYL net product revenue rose 95% year-over-year to $41.2 million; company now expects full-year 2026 AUCATZYL net product revenue at or exceeding the upper end of $150 million

→Mixed quarter

Product revenue growth (95% year-over-year) and a reported gross margin of 57% are strong, and the full-year revenue outlook was raised. Operating and net losses remain large, shareholders' equity fell to $27,396 thousand, and total liabilities exceed $495 million, so the balance sheet and funding runway carry significant weight.

Revenue
$41.2M
AUCATZYL net product revenue
$41.2 million (three months ended Sep 30, 2026)
95% y/y
Gross margin · other
57%
FY2026 outlook
AUCATZYL net product revenue at or exceeding the upper end of $150 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net (three months ended Sep 30, 2026)GAAP$41.2M–95%
Total revenue, net (three months ended Sep 30, 2026)GAAP$41.24M––
Product revenue, net (nine months ended Sep 30, 2026)GAAP$113.1M––
Total revenue, net (nine months ended Sep 30, 2026)GAAP$113.1M––
Cost of sales (three months ended Sep 30, 2026)GAAP$17.9M––
Cost of sales (nine months ended Sep 30, 2026)GAAP−$62.96M––
Gross margin (three months ended Sep 30, 2026)other57%––
Research and development expenses, net (three months ended Sep 30, 2026)GAAP$30.9M––
Research and development expenses, net (nine months ended Sep 30, 2026)GAAP−$80.01M––
Selling, general and administrative expenses (three months ended Sep 30, 2026)GAAP$35.9M––
Selling, general and administrative expenses (nine months ended Sep 30, 2026)GAAP−$117.1M––
Loss from operations (three months ended Sep 30, 2026)GAAP$43.5M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$146.9M––
Total other (expenses) income, net (three months ended Sep 30, 2026)GAAP−$12.04M––
Total other (expenses) income, net (nine months ended Sep 30, 2026)GAAP−$18.07M––
Income tax benefit (expense) (three months ended Sep 30, 2026)GAAP$489K––
Net loss (three months ended Sep 30, 2026)GAAP$55.1M––
Net loss (nine months ended Sep 30, 2026)GAAP−$165.8M––
Basic and diluted net loss per ordinary share (three months ended Sep 30, 2026)GAAP$(0.21)––
Basic and diluted net loss per ordinary share (nine months ended Sep 30, 2026)GAAP$(0.62)––
Total comprehensive loss (three months ended Sep 30, 2026)GAAP−$54.61M––
Cash, cash equivalents and marketable securities (at Sep 30, 2026)other$248.4M––

Segments

SegmentRevenueq/qy/y
AUCATZYL net product revenuePer the company, net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales.$41.2 million (three months ended Sep 30, 2026)–95%
License revenueNo driver is given in the filing for this line.— (three months ended Sep 30, 2026; $50 thousand in the same period of 2025)––

FY2026 outlook

  • RevenueAUCATZYL net product revenue at or exceeding the upper end of $150 million
  • NoteCash, cash equivalents and marketable securities expected to be sufficient to fund operations into Q2 2028, based on current operating plans, anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from the Perceptive credit facility (company statement).

Capital returns

  • No share repurchases or dividends are reported in the filing.

What drove it

  • Company explanation: AUCATZYL revenue growth was primarily driven by growth within existing authorized treatment centers as physicians gain experience with the therapy, and supported by real-world data reported through the ROCCA consortium.
  • Company explanation: gross margin improvement over the prior year was primarily driven by a reduction in manufacturing cost per batch, reflecting increased volumes and ongoing operational efficiency initiatives, and by lower inventory reserves and write-offs compared with the same period in 2025.
  • Company explanation: the R&D increase was primarily due to higher clinical manufacturing supply costs driven by clinical development activities, partially offset by lower salaries and other employment-related costs.
  • Company explanation: the SG&A decrease was primarily due to lower salaries, other employment-related costs and professional fees supporting commercialization activities in the US and UK.
  • Company explanation: the cash balance increase in the quarter was primarily driven by net cash inflows from the Perceptive Advisors senior secured note facility.
  • The company raised its full-year 2026 AUCATZYL net product revenue expectation to at or exceeding the upper end of $150 million.

Concerns

  • Loss from operations was $43.5 million and net loss was $55.1 million for the quarter; nine-month net loss was $(165,800) thousand.
  • Total shareholders' equity fell to $27,396 thousand at Sep 30, 2026 from $178,129 thousand at Dec 31, 2025, while total liabilities rose to $495,663 thousand from $410,939 thousand.
  • The company's funding runway into Q2 2028 depends on AUCATZYL revenues and the $100 million combined first and second tranches from the Perceptive credit facility, as stated in the filing.
  • Other (expense) income, net was $(12,045) thousand in the quarter against $(6,965) thousand a year earlier; the filing does not explain this line.
  • The filing's safety information reports, for the FELIX study, 9 patients (9%) with fatal adverse reactions, and a warning covering cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies.
  • The company moved the first progressive MS data presentation to ECTRIMS Global in October 2027, following KOL feedback that longer follow-up is required.

What to watch

  • Delivery against the full-year 2026 AUCATZYL net product revenue expectation of at or exceeding the upper end of $150 million.
  • Gross margin trajectory from 55% in Q2 2026 to 57% in Q3 2026, and whether manufacturing efficiency gains continue.
  • Timing of Perceptive credit facility tranches and the company's cash runway into Q2 2028.
  • Data from the CARLYSLE trial in SLE (ACR, November 10, 2026) and the ALARIC Phase 1 trial in light-chain amyloidosis (ASH, December 12, 2026).
  • CATULUS Phase 2 pediatric r/r B-ALL data by year-end 2027, LUMINA Phase 2 lupus nephritis data in 2028, and BOBCAT Phase 1 progressive MS data in October 2027.
  • R&D and SG&A trends as clinical development and commercialization activities continue.

Balance sheet and cash flow

  • Cash and cash equivalents: $245,405 thousand at Sep 30, 2026, compared with $104,132 thousand at Dec 31, 2025.
  • Marketable securities (available-for-sale debt securities): $2,972 thousand at Sep 30, 2026, compared with $196,578 thousand at Dec 31, 2025.
  • Total current assets: $366,784 thousand at Sep 30, 2026, compared with $435,915 thousand at Dec 31, 2025.
  • Total assets: $523,059 thousand at Sep 30, 2026, compared with $589,068 thousand at Dec 31, 2025.
  • Total current liabilities: $98,647 thousand at Sep 30, 2026, compared with $73,440 thousand at Dec 31, 2025.
  • Total liabilities: $495,663 thousand at Sep 30, 2026, compared with $410,939 thousand at Dec 31, 2025.
  • Total shareholders' equity: $27,396 thousand at Sep 30, 2026, compared with $178,129 thousand at Dec 31, 2025.
  • The company states that the increase in cash, cash equivalents and marketable securities from $201.6 million at June 30, 2026 to $248.4 million at Sep 30, 2026 was primarily driven by net cash inflows from the senior secured note facility from Perceptive Advisors.
  • Operating cash flow and free cash flow are not reported in the filing.

Analysis

Autolus reported AUCATZYL net product revenue of $41.2 million for the three months ended September 30, 2026, against $21.1 million a year earlier, an increase of 95% as stated in the release. For the nine months, product revenue was $113,128 thousand against $51,049 thousand. The company attributes the quarter's growth to increasing demand within existing treatment centers and expansion into new centers, supplemented by UK sales. Cost of sales fell to $17.9 million from $28.6 million, and the company reports a gross margin of 57%, up from 55% in the second quarter of 2026 and from a negative gross margin in the year-earlier quarter. Per the company, the year-over-year improvement reflects lower manufacturing cost per batch from higher volumes and efficiency initiatives, as well as lower inventory reserves and write-offs.

Operating spend moved in different directions. Research and development expenses rose to $30.9 million from $27.9 million, which the company links to higher clinical manufacturing supply costs. Selling, general and administrative expenses were $35.9 million against $36.3 million a year earlier. Loss from operations narrowed to $43.5 million from $71.6 million, and net loss narrowed to $55.1 million from $79.1 million. Basic and diluted net loss per ordinary share was $(0.21) against $(0.30). Total other expenses, net increased to $(12,045) thousand from $(6,965) thousand, and the filing does not explain this line in the quarter.

The balance sheet shows a different picture from the income statement. Cash, cash equivalents and marketable securities rose to $248.4 million from $201.6 million at June 30, 2026, which the company attributes primarily to net cash inflows from the Perceptive Advisors senior secured note facility. Total liabilities were $495,663 thousand at September 30, 2026, up from $410,939 thousand at December 31, 2025, and shareholders' equity was $27,396 thousand, down from $178,129 thousand. The company states that current and projected cash, together with AUCATZYL revenues and the combined first and second tranches totaling $100 million from the Perceptive credit facility, will fund operations into Q2 2028.

The company now expects full-year 2026 AUCATZYL net product revenue at or exceeding the upper end of $150 million. The filing does not print an earlier figure for this outlook beyond the phrase "from prior guidance", so the size of the change cannot be measured from the document. No operating cash flow, free cash flow, or capital returns are reported.

On the pipeline, the release moves the first progressive MS data presentation to ECTRIMS Global in October 2027, citing KOL feedback that longer follow-up is needed. Data are expected from CARLYSLE at ACR on November 10, 2026, from ALARIC at ASH on December 12, 2026, from CATULUS by year-end 2027, and from LUMINA in 2028. Investors should weigh the strong revenue and margin trend against the scale of losses, the reduced equity, the dependence on the credit facility tranches for runway, and the safety warnings described in the filing.

Management, verbatim

We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives,

Dr. Christian Itin, Chief Executive Officer

AUCATZYL's performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus' proven manufacturing and commercial capabilities.

Dr. Christian Itin, Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year and prior-quarter percentage changes for cost of sales, R&D, SG&A, and loss from operations (not printed as percentages in the filing).
  • Numeric prior-year gross margin (the filing says only 'negative' for Q3 2025).
  • Prior-year cash, cash equivalents and marketable securities figure for September 30, 2025 (not printed).
  • Prior-quarter values for product revenue, operating expenses, loss from operations, and net loss (the filing prints prior-quarter figures only for gross margin and cash).
  • Operating cash flow, free cash flow, and capital expenditures.
  • Prior guidance figures beyond the phrase 'from prior guidance'; the previous outlook document was not provided.
  • Share repurchase and dividend data (none reported).
  • Consensus estimates and share price reaction (not in the documents).
  • Explanation of the increase in total other expenses, net in the quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readAUTL · Q2 2026 · ended June 30, 2026

AUCATZYL® net product revenue reached $45.7 million in Q2 2026, gross margin rose to 55%, and Autolus increased FY 2026 net product revenue guidance to $140 million to $150 million.

✓Strong quarter

AUCATZYL revenue increased 119% year-over-year to $45.7 million and rose from $26.2 million in the prior quarter, while gross margin improved to 55% from 6% in Q1 2026. The company raised full-year revenue guidance and secured a credit facility with $75 million funded at close, although it remained loss-making and selling, general and administrative expenses increased.

Revenue
45,689
AUCATZYL® (obecabtagene autoleucel; obe-cel)
$45.7M
119% y/y
Gross margin · other
55%
FY 2026 outlook
$140 million to $150 million
GM 65-70%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, netother$45.67M–119%
License revenueother17––
Total revenue, netother45,689––
Cost of salesother(20,468)––
Gross marginother55%––
Research and development expenses, netother(27,898)––
Selling, general and administrative expensesother(41,161)––
Loss from operationsother(43,838)––
Total other income (expenses), netother5,192––
Income tax expenseother(465)––
Net lossother(39,111)––
Total other comprehensive income (loss), net of taxother526––
Total comprehensive lossother−$38.59M––
Basic and diluted net loss per ordinary shareother$(0.15)––
Weighted-average basic and diluted ordinary sharesother266,158,829––
Six-month product revenue, netother$71.89M––
Six-month license revenueother17––
Six-month total revenue, netother71,907––
Six-month cost of salesother(45,036)––
Six-month research and development expenses, netother(49,108)––
Six-month selling, general and administrative expensesother(81,114)––
Six-month loss from operationsother(103,351)––
Six-month total other income (expenses), netother(6,030)––
Six-month income tax expenseother(1,328)––
Six-month net lossother(110,709)––
Six-month total other comprehensive income (loss), net of taxother(745)––
Six-month total comprehensive lossother−$111.5M––
Six-month basic and diluted net loss per ordinary shareother$(0.42)––
Six-month weighted-average basic and diluted ordinary sharesother266,151,170––

Segments

SegmentRevenueq/qy/y
AUCATZYL® (obecabtagene autoleucel; obe-cel)Increasing product demand within existing treatment centers, expansion into new centers, and contribution from UK sales in the second quarter of launch in that market.$45.7M–119%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY 2026 outlook

  • Revenue$140 million to $150 million
  • Gross margin65-70%
  • NoteAutolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations into Q2 2028.

What drove it

  • Net revenue growth was primarily driven by increasing product demand within existing treatment centers, expansion into new centers, and UK sales.
  • Gross-margin improvement was primarily driven by reduced manufacturing cost per batch from increased volumes and operational efficiency initiatives, plus lower inventory reserves and write-offs compared with the prior-year period.
  • Research and development expense increased because of clinical-trial and clinical-manufacturing supply costs, partially offset by lower salaries and other employment-related costs.
  • Selling, general and administrative expense increased due to salaries, other employment-related costs and professional fees supporting US and UK commercialization, as well as termination-related expenses.
  • The April 2026 efficiency initiative included a workforce reduction affecting approximately 13% of the existing overall workforce and is expected to reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027.

Concerns

  • Net loss was $39.1 million for the three months ended June 30, 2026.
  • Selling, general and administrative expenses increased to $41.2 million from $30.3 million in the prior-year period.
  • Research and development expenses increased to $27.9 million from $27.4 million in the prior-year period.
  • Cash, cash equivalents and marketable securities declined to $201.6 million at June 30, 2026, from $229.4 million at March 31, 2026.
  • Access to the additional $150 million under the credit facility is contingent on achievement of certain pre-specified revenue milestones.

What to watch

  • Longer-term follow-up data from the CARLYSLE trial in severe refractory systemic lupus erythematosus are expected by year-end 2026.
  • Initial clinical data from the ALARIC Phase 1 trial in light-chain amyloidosis are expected by year-end 2026.
  • Initial clinical data from the BOBCAT Phase 1 trial in progressive MS are planned for Q1 2027, with a larger data set with longer follow up planned for 2H 2027.
  • Phase 2 data from the CATULUS trial in pediatric r/r B-ALL are expected by year-end 2027.
  • Phase 2 data from the LUMINA trial in lupus nephritis are expected in 2028.
  • Continued AUCATZYL adoption across existing and new treatment centers, UK sales contribution, and progress toward the stated 65-70% peak estimate for adult ALL margins.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities at June 30, 2026, totaled $201.6 million, as compared to $229.4 million at March 31, 2026.
  • Cash and cash equivalents were $ 171,414 at June 30, 2026, compared with $ 104,132 at December 31, 2025.
  • Marketable securities - Available-for-sale debt securities were $ 30,216 at June 30, 2026, compared with $ 196,578 at December 31, 2025.
  • Total current assets were $ 336,091 at June 30, 2026, compared with $ 435,915 at December 31, 2025.
  • Total assets were $ 493,226 at June 30, 2026, compared with $ 589,068 at December 31, 2025.
  • Total current liabilities were $ 68,790 at June 30, 2026, compared with $ 73,440 at December 31, 2025.
  • Total liabilities were $ 418,387 at June 30, 2026, compared with $ 410,939 at December 31, 2025.
  • Total shareholders' equity was $ 493,226 at June 30, 2026, compared with $ 589,068 at December 31, 2025.
  • An initial $75 million principal amount of notes was issued to Perceptive on July 30, 2026.
  • An additional $25 million in aggregate principal amount will be available at Autolus’ option for up to six months post-closing.
  • An additional $150 million in aggregate principal amount of subsequent capital may become available in separate tranches upon achievement of certain pre-specified revenue milestones.

Analysis

Autolus reported a strong commercial quarter for AUCATZYL. Net product revenue was $45.7 million, compared with $20.9 million in the prior-year period and $26.2 million in the three months ending March 31, 2026. Management attributed the revenue increase to higher demand at existing treatment centers, new centers coming online, and UK sales in the second quarter of launch in that market. The company raised FY 2026 AUCATZYL net product revenue guidance to $140 million to $150 million from between $120 million to $135 million.

The principal financial change was the improvement in gross margin to 55% in Q2 2026 from 6% in Q1 2026. Cost of sales declined to $20.5 million from $24.4 million in the prior-year period even as product revenue increased. The company attributed the margin improvement to lower manufacturing cost per batch from higher volumes and efficiency initiatives, alongside lower inventory reserves and write-offs. Management stated an expectation for improvement over time toward a 65-70% peak estimate for adult ALL margins.

The company remained loss-making despite the revenue and margin progress. Loss from operations was $43.8 million and net loss was $39.1 million, compared with $61.2 million and $47.9 million, respectively, in the prior-year quarter. R&D expense increased to $27.9 million due to clinical-trial and clinical-manufacturing supply costs. SG&A increased to $41.2 million, reflecting commercialization support in the US and UK plus termination-related costs from the April 2026 operational-efficiency initiative.

Liquidity was supported by $201.6 million of cash, cash equivalents and marketable securities at June 30, 2026, although this was down from $229.4 million at March 31, 2026. Subsequent to quarter-end, Autolus issued an initial $75 million principal amount under a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. The company said the combined first and second tranches total $100 million and, together with anticipated AUCATZYL net revenues, are expected to fund operations into Q2 2028.

Pipeline milestones remain important alongside commercialization. The company expects CARLYSLE and ALARIC updates by year-end 2026, initial BOBCAT data in Q1 2027, CATULUS Phase 2 data by year-end 2027, and LUMINA Phase 2 data in 2028. Execution priorities are sustaining AUCATZYL demand growth, translating volume into further gross-margin improvement, managing commercialization expenses, and meeting the revenue milestones associated with subsequent credit-facility tranches.

Management, verbatim

In the second quarter we achieved substantial sales growth in the ongoing AUCATZYL launch, driven by physician enthusiasm and expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online.

Dr. Christian Itin, Chief Executive Officer of Autolus

The increased product volumes, combined with the ongoing operational efficiency initiatives announced in April, together drove a significant step up in gross margin. We expect improvement over time towards our peak estimate for adult ALL margins of 65-70%.

Dr. Christian Itin, Chief Executive Officer of Autolus

We see adoption of AUCATZYL in adult r/r B-ALL as a key near-term value driver. Longer-term, we believe there are meaningful opportunities to expand into new indications to continue driving scalable growth by leveraging obe-cel’s favorable profile and Autolus’ proven manufacturing and commercial capabilities.

Dr. Christian Itin, Chief Executive Officer of Autolus

Not in the filing

stated, not guessed
  • GAAP or non-GAAP accounting basis was not explicitly stated in the provided filing text.
  • Non-GAAP revenue, gross margin, operating income, net income, EPS, and reconciliations were not reported.
  • Prior-year numerical gross margin for Q2 2025 was not reported; the filing stated only that gross margin was negative in all prior quarters in 2025.
  • Prior-quarter total revenue, cost of sales, operating expenses, operating loss, net loss, and EPS were not reported.
  • Operating cash flow and free cash flow were not reported.
  • A numerical debt balance at June 30, 2026 was not reported.
  • Share repurchases, dividends, and other shareholder capital-return activity were not reported.
  • Guidance for operating expenses and tax rate was not reported.
  • A prior earnings release outlook section was not provided, so no reported results were compared against prior guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about AUTL earnings dates

When is Autolus Therapeutics's next earnings date?
AlphAI has no date for AUTL yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.